



US 20100227924A1

(19) **United States**

(12) **Patent Application Publication**
Cirpus et al.

(10) **Pub. No.: US 2010/0227924 A1**

(43) **Pub. Date: Sep. 9, 2010**

(54) **METHOD FOR PRODUCING
POLYUNSATURATED FATTY ACIDS**

Sep. 7, 2006 (EP) 06120309.7

Publication Classification

(75) Inventors: **Petra Cirpus**, Waldsee (DE); **Jörg Bauer**, Limburgerhof (DE); **Xiao Qiu**, Saskatoon (CA); **Guohai Wu**, Saskatoon (CA); **Bifang Cheng**, Saskatoon (CA); **Martin Truksa**, Edmonton (CA); **Tom Wetjen**, Mannheim (DE)

(51) **Int. Cl.**
A61K 31/20 (2006.01)
C12N 15/82 (2006.01)
A01H 5/00 (2006.01)
C07H 21/04 (2006.01)
A23D 9/00 (2006.01)
(52) **U.S. Cl. 514/558; 800/281; 800/298; 536/23.6; 426/601**

Correspondence Address:
CONNOLLY BOVE LODGE & HUTZ, LLP
P O BOX 2207
WILMINGTON, DE 19899 (US)

(57) **ABSTRACT**

The invention relates to a method for producing eicosapentanoic acid, docosapentanoic acid and/or docohexanoic acid in transgenic plants. According to said method, the plant is provided with at least one nucleic acid sequence coding for a polypeptide with a Δ6 desaturase activity, at least one nucleic acid sequence coding for a polypeptide with a Δ6 elongase activity, at least one nucleic acid sequence coding for a polypeptide with a Δ5 desaturase activity, and at least one nucleic acid sequence coding for a polypeptide with a Δ5 elongase activity being modified in relation to the nucleic acid sequence in the organism from which the sequence originates, such that it is adapted to the codon use in at least one type of plant. For the production of docosahexanoic acid, at least one nucleic acid sequence coding for a polypeptide with a Δ4 desaturase activity is also introduced into the plant.

(73) Assignee: **BASF Plant Science GmbH**, Ludwigshafen (DE)

(21) Appl. No.: **12/280,090**

(22) PCT Filed: **Feb. 21, 2007**

(86) PCT No.: **PCT/EP2007/051675**

§ 371 (c)(1),
(2), (4) Date: **Aug. 20, 2008**

(30) **Foreign Application Priority Data**

Feb. 21, 2006 (DE) 102006008030.0

METHOD FOR PRODUCING POLYUNSATURATED FATTY ACIDS

[0001] The present invention relates to a process for the production of eicosapentaenoic acid, docosapentaenoic acid and/or docosahexaenoic acid in transgenic plants, providing in the plant at least one nucleic acid sequence which codes for a polypeptide having a $\Delta 6$ -desaturase activity; at least one nucleic acid sequence which codes for a polypeptide having a $\Delta 6$ -elongase activity; at least one nucleic acid sequence which codes for a polypeptide having a $\Delta 5$ -desaturase activity; and at least one nucleic acid sequence which codes for a polypeptide having a $\Delta 5$ -elongase activity,

where the nucleic acid sequence which codes for a polypeptide having a $\Delta 5$ -elongase activity is modified by comparison with the nucleic acid sequence in the organism from which the sequence is derived in that it is adapted to the codon usage in one or more plant species. In a preferred embodiment there is additionally provision of further nucleic acid sequences which code for a polypeptide having the activity of an $\omega 3$ -desaturase and/or of a $\Delta 4$ -desaturase in the plant.

[0002] In a further preferred embodiment there is provision of further nucleic acid sequences which code for acyl-CoA dehydrogenase(s), acyl-ACP (acyl carrier protein) desaturase (s), acyl-ACP thioesterase(s), fatty acid acyl transferase(s), acyl-CoA:lysophospholipid acyl transferase(s), fatty acid synthase(s), fatty acid hydroxylase(s), acetyl-coenzyme A carboxylase(s), acyl-coenzyme A oxidase(s), fatty acid desaturase(s), fatty acid acetylenases, lipoxygenases, triacylglycerol lipases, allene oxide synthases, hydroperoxide lyases or fatty acid elongase(s) in the plant.

[0003] The invention furthermore relates to recombinant nucleic acid molecules comprising at least one nucleic acid sequence which codes for a polypeptide having a $\Delta 6$ -desaturase activity; at least one nucleic acid sequence which codes for a polypeptide having a $\Delta 5$ -desaturase activity; at least one nucleic acid sequence which codes for a polypeptide having a $\Delta 6$ -elongase activity; and at least one nucleic acid sequence which codes for a polypeptide having a $\Delta 5$ -elongase activity and which is modified by comparison with the nucleic acid sequence in the organism from which the sequence originates in that it is adapted to the codon usage in one or more plant species.

[0004] A further part of the invention relates to oils, lipids and/or fatty acids which have been produced by the process according to the invention, and to their use.

[0005] Finally, the invention also relates to transgenic plants which have been produced by the process of the invention or which comprise a recombinant nucleic acid molecule of the invention, and to the use thereof as foodstuffs or feedstuffs.

[0006] Lipid synthesis can be divided into two sections: the synthesis of fatty acids and their binding to sn-glycerol-3-phosphate, and the addition or modification of a polar head group. Usual lipids which are used in membranes comprise phospholipids, glycolipids, sphingolipids and phosphoglycerides. Fatty acid synthesis starts with the conversion of acetyl-CoA into malonyl-CoA by acetyl-CoA carboxylase or into acetyl-ACP by acetyl transacylase. After condensation reaction, these two product molecules together form acetoacetyl-ACP, which is converted via a series of conden-

The production of the unsaturated fatty acids from these molecules is catalyzed by specific desaturases, either aerobically by means of molecular oxygen or anaerobically (regarding the fatty acid synthesis in microorganisms, see F. C. Neidhardt et al. (1996) *E. coli* and *Salmonella*. ASM Press: Washington, D.C., p. 612-636 and references cited therein; Lengeler et al. (Ed.) (1999) *Biology of Prokaryotes*. Thieme: Stuttgart, New York, and the references therein, and Magnusson, K., et al. (1993) *Microbiological Reviews* 57:522-542 and the references therein). To undergo the further elongation steps, the resulting phospholipid-bound fatty acids must be returned to the fatty acid CoA ester pool. This is made possible by acyl-CoA:lysophospholipid acyltransferases. Moreover, these enzymes are capable of transferring the elongated fatty acids from the CoA esters back to the phospholipids. If appropriate, this reaction sequence can be followed repeatedly.

[0007] Furthermore, fatty acids must subsequently be transported to various modification sites and incorporated into the triacylglycerol storage lipid. A further important step during lipid synthesis is the transfer of fatty acids to the polar head groups, for example by glycerol fatty acid acyltransferase (see Frentzen, 1998, *Lipid*, 100(4-5):161-166).

[0008] An overview of the biosynthesis of fatty acids in plants, desaturation, the lipid metabolism and the membrane transport of lipidic compounds, beta-oxidation, the modification of fatty acids, cofactors and the storage and assembly of triacylglycerol, including the references is given by the following papers: Kinney (1997) *Genetic Engineering*, Ed.: J K Setlow, 19:149-166; Ohlrogge and Browse (1995) *Plant Cell* 7:957-970; Shanklin and Cahoon (1998) *Annu. Rev. Plant Physiol. Plant Mol. Biol.* 49:611-641; Voelker (1996) *Genetic Engineering*, Ed.: J K Setlow, 18:111-13; Gerhardt (1992) *Prog. Lipid R.* 31:397-417; Gühnemann-Schafer & Kindl (1995) *Biochim. Biophys Acta* 1256:181-186; Kunau et al. (1995) *Prog. Lipid Res.* 34:267-342; Stymne et al. (1993) in: *Biochemistry and Molecular Biology of Membrane and Storage Lipids of Plants*, Ed.: Murata and Somerville, Rockville, American Society of Plant Physiologists, 150-158; Murphy & Ross (1998) *Plant Journal*. 13(1):1-16.

[0009] Depending on the desaturation pattern, two large classes of polyunsaturated fatty acids, the $\omega 6$ and the $\omega 3$ fatty acids; which differ with regard to their metabolism and their function, can be distinguished.

[0010] In the text which follows, polyunsaturated fatty acids are referred to as PUPA, PUFAs, LCPUFA or LCPUFAs (poly unsaturated fatty acids, PUFA, long chain poly unsaturated fatty acids, LCPUFA).

[0011] The fatty acid linoleic acid (18:2 ^{$\Delta 9,12$}) acts as starting material for the $\omega 6$ metabolic pathway, while the $\omega 3$ pathway proceeds via linolenic acid (18:3 ^{$\Delta 9,12,15$}). Linolenic acid is formed from linoleic acid by the activity of an $\omega 3$ -desaturase (Tocher et al. (1998) *Prog. Lipid Res.* 37: 73-117; Domergue et al. (2002) *Eur. J. Biochem.* 269: 4105-4113).

[0012] Mammals, and thus also humans, have no corresponding desaturase activity ($\Delta 12$ - and $\omega 3$ -desaturase) for the formation of the starting materials and must therefore take up these fatty acids (essential fatty acids) via the food. Starting with these precursors, the physiologically important polyunsaturated fatty acids arachidonic acid (=ARA, 20:4 ^{$\Delta 5,8,11,14$}), an $\omega 6$ -fatty acid and the two $\omega 3$ -fatty acids eicosapentaenoic acid (=EPA, 20:5 ^{$\Delta 5,8,11,14,17$}) and docosa-hexaenoic acid (=DHA, 22:6 ^{$\Delta 7,10,13,16,19$}).

[0013] The elongation of fatty acids, by elongases, by 2 or 4 C atoms is of crucial importance for the production of C_{20} - and C_{22} -PUFAs, respectively. This process proceeds via 4 steps. The first step is the condensation of malonyl-CoA onto the fatty acid acyl-CoA by ketoacyl-CoA synthase (KCS, hereinbelow referred to as elongase). This is followed by a reduction step (ketoacyl-CoA reductase, KCR), a dehydration step (dehydratase) and a final reduction step (enoyl-CoA reductase). It has been postulated that the elongase activity affects the specificity and rate of the entire process (Millar and Kunst (1997) *Plant Journal* 12:121-131).

[0014] Fatty acids and triacylglycerides have a multiplicity of applications in the food industry, in animal nutrition, in cosmetics and the pharmacological sector. Depending on whether they are free saturated or unsaturated fatty acids or else triacylglycerides with an elevated content of saturated or unsaturated fatty acids, they are suitable for very different applications. Thus, for example, lipids with unsaturated, specifically with polyunsaturated fatty acids, are preferred in human nutrition. The polyunsaturated ω 3-fatty acids are supposed to have a positive effect on the cholesterol level in the blood and thus on the prevention of heart disease. The risk of heart disease, strokes or hypertension can be reduced markedly by adding these ω 3-fatty acids to the food (Shimikawa (2001) *World Rev. Nutr. Diet.* 88: 100-108).

[0015] ω 3-fatty acids also have a positive effect on inflammatory, specifically on chronically inflammatory, processes in association with immunological diseases such as rheumatoid arthritis (Calder (2002) *Proc. Nutr. Soc.* 61: 345-358; Cleland and James (2000) *J. Rheumatol.* 27: 2305-2307). They are therefore added to foodstuffs, specifically to dietetic foodstuffs, or are employed in medicaments. ω 6-fatty acids such as arachidonic acid tend to have a negative effect in connection with these rheumatological diseases.

[0016] ω 3- and ω 6-fatty acids are precursors of tissue hormones, known as eicosanoids, such as the prostaglandins, which are derived from dihomo- γ -linolenic acid, arachidonic acid and eicosapentaenoic acid, and of the thromboxanes and leukotrienes, which are derived from arachidonic acid and eicosapentaenoic acid. Eicosanoids (known as the PG_2 series) which are formed from the Ω 6-fatty acids, generally promote inflammatory reactions, while eicosanoids (known as the PG_3 series) from Ω 3-fatty acids have little or no proinflammatory effect.

[0017] Polyunsaturated long-chain Ω 3-fatty acids such as eicosapentaenoic acid (=EPA, $C_{20}:5^{\Delta 5,8,11,14,17}$) or docosahexaenoic acid (=DHA, $C_{22}:6^{\Delta 4,7,10,13,16,19}$) are important components of human nutrition owing to their various roles in health aspects, including the development of the child brain, the functionality of the eyes, the synthesis of hormones and other signal substances, and the prevention of cardiovascular disorders, cancer and diabetes (Poulos, A (1995) *Lipids* 30:1-14; Horrocks, L A and Yeo Y K (1999) *Pharmacol Res* 40:211-225).

[0018] Owing to the present-day composition of human food, an addition of polyunsaturated ω 3-fatty acids, which are preferentially found in fish oils, to the food is particularly important. Thus, for example, polyunsaturated fatty acids such as docosahexaenoic acid (=DHA, $C_{22}:6^{\Delta 4,7,10,13,16,19}$) or eicosapentaenoic acid (=EPA, $C_{20}:5^{\Delta 5,8,11,14,17}$) are added to infant formula to improve the nutritional value. There is

[0019] The various fatty acids and triglycerides are mainly obtained from microorganisms such as *Mortierella* or *Schizochytrium* or from oil-producing plants such as soybeans, oilseed rape, and algae such as *Cryptothecodinium* or *Phaeodactylum* and others, being obtained, as a rule, in the form of their triacylglycerides (=triglycerides=triglycerols). However, they can also be obtained from animals, for example, fish. The free fatty acids are advantageously prepared by hydrolyzing the triacylglycerides. Very long-chain polyunsaturated fatty acids such as DHA, EPA, arachidonic acid (ARA, $C_{20}:4^{\Delta 5,8,11,14}$), dihomo- γ -linolenic acid (DHGL, $C_{20}:3^{\Delta 8,11,14}$) or docosapentaenoic acid (DPA, $C_{22}:5^{\Delta 7,10,13,16,19}$) are, however, not synthesized in oil crops such as oilseed rape, soybeans, sunflowers and safflower. Conventional natural sources of these fatty acids are fish such as herring, salmon, sardine, redfish, eel, carp, trout, halibut, mackerel, zander or tuna, or algae.

[0020] Owing to the positive characteristics of the polyunsaturated fatty acids, there has been no lack of attempts in the past to make available genes which are involved in the synthesis of these fatty acids or triglycerides for the production of oils in various organisms with a modified content of unsaturated fatty acids. Thus, WO 91/13972 and its US equivalent describe a Δ 9-desaturase. WO 93/11245 claims a Δ 15-desaturase and WO 94/11516 a Δ 12-desaturase. Further desaturases are described, for example, in EPA-0 550 162, WO 94/18337, WO 97/30582, WO 97/21340, WO 95/18222, EPA-0 794 250, Stukey et al. (1990) *J. Biol. Chem.*, 265: 20144-20149, Wada et al. (1990) *Nature* 347: 200-203 or Huang et al. (1999) *Lipids* 34: 649-659. However, the biochemical characterization of the various desaturases has been insufficient to date since the enzymes, being membrane-bound proteins, present great difficulty in their isolation and characterization (McKeon et al. (1981) *Methods in Enzymol.* 71: 12141-12147, Wang et al. (1988) *Plant Physiol. Biochem.*, 26: 777-792).

[0021] As a rule, membrane-bound desaturases are characterized by being introduced into a suitable organism which is subsequently analyzed for enzyme activity by analyzing the starting materials and the products. Δ 6-Desaturases are described in WO 93/06712, U.S. Pat. No. 5,614,393, WO 96/21022, WO 00/21557 and WO 99/27111. The application of this enzyme for the production of fatty acids in transgenic organisms is described in WO 98/46763, WO 98/46764 and WO 98/46765. The expression of various desaturases and the formation of polyunsaturated fatty acids is also described and claimed in WO 99/64616 or WO 98/46776. As regards the expression efficacy of desaturases and its effect on the formation of polyunsaturated fatty acids, it must be noted that the expression of a single desaturase as described to date has only resulted in low contents of unsaturated fatty acids/lipids such as, for example, γ -linolenic acid and stearidonic acid.

[0022] There have been a number of attempts in the past to obtain elongase genes. Millar and Kunst (1997) *Plant Journal* 12:121-131 and Millar et al. (1999) *Plant Cell* 11:825-838 describe the characterization of plant elongases for the synthesis of monounsaturated long-chain fatty acids ($C_{22}:1$) and for the synthesis of very long-chain fatty acids for the formation of waxes in plants (C_{25} - C_{32}). The synthesis of arachidonic acid and EPA is described, for example, in WO 01/59128, WO 00/12720, WO 02/077213 and WO 02/08401. The synthesis of polyunsaturated C_{24} -fatty acids is

[0023] Especially suitable microorganisms for the production of PUFAs are microalgae such as *Phaeodactylum tricornutum*, *Porphyridium* species, *Thraustochytrium* species, *Schizochytrium* species or *Cryptocodinium* species, ciliates such as *Stylonychia* or *Colpidium*, fungi such as *Mortierella*, *Entomophthora* or *Mucor* and/or mosses such as *Physcomitrella*, *Ceratodon* and *Marchantia* (R. Vazhappilly & F. Chen (1998) *Botanica Marina* 41: 553-558; K. Totani & K. Oba (1987) *Lipids* 22: 1060-1062; M. Akimoto et al. (1998) *Appl. Biochemistry and Biotechnology* 73: 269-278). Strain selection has resulted in the development of a number of mutant strains of the microorganisms in question which produce a series of desirable compounds including PUFAs. However, the mutation and selection of strains with an improved production of a particular molecule such as the polyunsaturated fatty acids is a time-consuming and difficult process. Moreover, only limited amounts of the desired polyunsaturated fatty acids such as DPA, EPA or ARA can be produced with the aid of the abovementioned microorganisms; in addition, they are generally obtained as fatty acid mixtures. This is why recombinant methods are preferred whenever possible.

[0024] Higher plants comprise polyunsaturated fatty acids such as linoleic acid (C18:2) and linolenic acid (C18:3). ARA, EPA and DHA are found not at all in the seed oil of higher plants, or only in minuscule amounts (E. Ucciani: *Nouveau Dictionnaire des Huiles Végétales* [New Dictionary of the Vegetable Oils]. Technique & Documentation—Lavoisier, 1995. ISBN: 2-7430-0009-0). However, the production of LCPUFAs in higher plants, preferably in oil crops such as oilseed rape, linseed, sunflowers and soybeans, would be advantageous since large amounts of high-quality LCPUFAs for the food industry, animal nutrition and pharmaceutical purposes might be obtained economically. To this end, it is advantageous to introduce, into oilseeds, genes which encode enzymes of the LCPUFA biosynthesis via recombinant methods and to express them therein. These genes encode for example $\Delta 6$ -desaturases, $\Delta 6$ -elongases, $\Delta 5$ -desaturases or $\Delta 4$ -desaturases. These genes can advantageously be isolated from microorganisms and lower plants which produce LCPUFAs and incorporate them in the membranes or triacylglycerides. Thus, it has already been possible to isolate $\Delta 6$ -desaturase genes from the moss *Physcomitrella patens* and $\Delta 6$ -elongase genes from *P. patens* and from the nematode *C. elegans*.

[0025] Transgenic plants which comprise and express genes encoding LCPUFA biosynthesis enzymes and which, as a consequence, produce LCPUFAs have been described, for example, in DE-A-102 19 203 (process for the production of polyunsaturated fatty acids in plants).

[0026] However, these plants produce LCPUFAs in amounts which require further optimization for processing the oils which are present in the plants. Thus, the ARA content in the plants described in DE-A-102 19 203 is only 0.4 to 2% and the EPA content only 0.5 to 1%, in each case based on the total lipid content of the plant.

[0027] To make possible the fortification of food and of feed with polyunsaturated, long-chain fatty acids, there is therefore a great need for a simple, inexpensive process for the production of polyunsaturated, long-chain fatty acids, specifically in plant systems.

[0028] One object of the invention is therefore to provide a

or docosahexaenoic acid can be produced in large quantities and inexpensively in transgenic plants.

[0029] It has now surprisingly been found that the yield of long-chain polyunsaturated fatty acids, especially eicosapentaenoic, docosapentaenoic acid and/or docosahexaenoic acid, can be increased by expressing an optimized $\Delta 5$ -elongase sequence in transgenic plants.

[0030] The PUFAs produced by the process of the invention comprise a group of molecules which higher animals are no longer able to synthesize and thus must consume, or which higher animals are no longer able to produce themselves in sufficient amounts and thus must consume additional amounts thereof, although they can easily be synthesized by other organisms such as bacteria.

[0031] Accordingly, the object of the invention is achieved by the process of the invention for producing eicosapentaenoic acid, docosapentaenoic acid and/or docosahexaenoic acid in a transgenic plant, comprising the provision in the plant of at least one nucleic acid sequence which codes for a polypeptide having a $\Delta 6$ -desaturase activity; at least one nucleic acid sequence which codes for a polypeptide having a $\Delta 6$ -elongase activity; at least one nucleic acid sequence which codes for a polypeptide having a $\Delta 5$ -desaturase activity; and at least one nucleic acid sequence which codes for a polypeptide having a $\Delta 5$ -elongase activity, where the nucleic acid sequence which codes for a polypeptide having a $\Delta 5$ -elongase activity is modified by comparison with the nucleic acid sequence in the organism from which the sequence is derived in that it is adapted to the codon usage in one or more plant species. To produce DHA it is additionally necessary to provide at least one nucleic acid sequence which codes for a polypeptide having a $\Delta 4$ -desaturase activity in the plant.

[0032] The “provision in the plant” means in the context of the present invention that measures are taken so that the nucleic acid sequences coding for a polypeptide having a $\Delta 6$ -desaturase activity, a polypeptide having a $\Delta 6$ -elongase activity, a polypeptide having a $\Delta 5$ -desaturase activity and a polypeptide having a $\Delta 5$ -elongase activity are present together in one plant. The “provision in the plant” thus comprises the introduction of the nucleic acid sequences into the plant both by transformation of a plant with one or more recombinant nucleic acid molecules which comprise said nucleic acid sequences, and by crossing suitable parent plants which comprise one or more of said nucleic acid sequences.

[0033] The nucleic acid sequence which codes for a polypeptide having a $\Delta 5$ -elongase activity is modified according to the invention by comparison with the nucleic acid sequence in the organism from which the sequence originates in that it is adapted to the codon usage in one or more plant species. This means that the nucleic acid sequence has been specifically optimized for the purpose of the invention without the amino acid sequence encoded by the nucleic acid sequence having been altered thereby.

[0034] The genetic code is redundant because it uses 61 codons in order to specify 20 amino acids. Therefore, most of the 20 proteinogenic amino acids are therefore encoded by a plurality of triplets (codons). The synonymous codons which specify an individual amino acid are, however, not used with the same frequency in a particular organism; on the contrary there are preferred codons which are frequently used, and codons which are used more rarely. These differences in

lower translation efficiency of rarely occurring codons might be that the corresponding aminoacyl-tRNA pools are exhausted and thus no longer available for protein synthesis.

[0035] In addition, different organisms prefer different codons. For this reason, for example, the expression of a recombinant DNA derived from a mammalian cell frequently proceeds only suboptimally in *E. coli* cells. It is therefore possible in some cases to increase expression by replacing rarely used codons with frequently used codons. Without wishing to be bound to one theory, it is assumed that the codon-optimized DNA sequences make more efficient translation possible, and the mRNAs formed therefrom possibly have a greater half-life in the cell and therefore are available more frequently for translation. From what has been said above, it follows that codon optimization is necessary only if the organism in which the nucleic acid sequence is to be expressed differs from the organism from which the nucleic acid sequence is originally derived.

[0036] For many organisms of which the DNA sequence of a relatively large number of genes is known there are tables from which the frequency of use of particular codons in the respective organism can be taken. It is possible with the aid of these tables to translate protein sequences with relatively high accuracy back into a DNA sequence which comprises the codons preferred in the respective organism for the various amino acids of the protein. Tables on codon usage can be found inter alia at the following Internet address: <http://www.kazusa.or.jp/Kodon/E.html>. In addition, several companies provide software for gene optimization, such as, for example, Entelechon (Software Leto) or Geneart (Software GeneOptimizer).

[0037] Adaptation of the sequences to the codon usage in a particular organism can take place with the aid of various criteria. On the one hand, it is possible to use for a particular amino acid always the codon which occurs most frequently in the selected organism but, on the other hand, the natural frequency of the various codons can also be taken into account, so that all the codons for a particular amino acid are incorporated into the optimized sequence according to their natural frequency. Selection of the position at which a particular base triplet is used can take place at random in this case. The DNA sequence was adapted according to the invention taking account of the natural frequency of individual codons, it also being suitable to use the codons occurring most frequently in the selected organism.

[0038] It is particularly preferred for a nucleic acid sequence from *Ostreococcus tauri* which codes for a polypeptide having a $\Delta 5$ -elongase activity, such as, for example, the polypeptide depicted in SEQ ID No. 110, to be adapted at least to the codon usage in oilseed rape, soybean and/or flax. The nucleic acid sequence originally derived from *Ostreococcus tauri* is preferably the sequence depicted in SEQ ID No. 109. The DNA sequence coding for the $\Delta 5$ -elongase is adapted in at least 20% of the positions, preferably in at least 30% of the positions, particularly preferably in at least 40% of the positions and most preferably in at least 50% of the positions to the codon usage in oilseed rape, soybean and/or flax.

[0039] The nucleic acid sequence used is most preferably the sequence indicated in SEQ ID No. 64.

[0040] It will be appreciated that the invention also encompasses those codon-optimized DNA sequences which code

tions by comparison with the wild-type sequence but which still has substantially the same activity as the wild-type protein.

[0041] The nucleic acid sequence which codes for a polypeptide having a $\Delta 6$ -desaturase activity is preferably selected from the group consisting of:

a) nucleic acid sequences having the sequence depicted in SEQ ID No. 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39 or 41, preferably having the sequence depicted in SEQ ID No. 1,

b) nucleic acid sequences which code for the amino acid sequence indicated in SEQ ID No. 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40 or 42, preferably in SEQ ID No. 2,

c) nucleic acid sequences which hybridize with the complementary strand of the nucleic acid sequences indicated a) or b) above, in particular of the nucleic acid sequence indicated in SEQ ID No. 1, under stringent conditions,

d) nucleic acid sequences which are at least 60%, 65%, 70%, 75% or 80%, preferably at least 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89% or 90%, particularly preferably at least 91%, 92%, 93%, 94% or 95% and especially at least 96%, 97%, 98% or 99%, identical to the nucleic acid sequences indicated in a) or b) above, especially to the sequence indicated in SEQ ID No. 1, and

e) nucleic acid sequences which code for an amino acid sequence and which have at least one, for example 2, 3, 4, 5, 6, 7 or 8, preferably all of the amino acid pattern indicated in SEQ ID No. 43, 44, 45, 46, 47, 48, 49 or 50.

[0042] Amino acid pattern means short amino acid sequences which preferably comprise less than 50, particularly preferably less than 40 and especially from 10 to 40 and even more preferably from 10 to 30 amino acids.

[0043] For the present invention, the identity is ascertained preferably over the full length of the nucleotide or amino acid sequences of the invention, for example for the nucleic acid sequence indicated in SEQ ID NO: 64 over the full length of 903 nucleotides.

[0044] The nucleic acid sequence which codes for a polypeptide having a $\Delta 6$ -elongase activity is preferably selected from the group consisting of:

a) nucleic acid sequences having the sequence depicted in SEQ ID No. 171, 173, 175, 177, 179, 181 or 183, especially having the sequence depicted in SEQ ID No. 171,

b) nucleic acid sequences which code for the amino acid sequence indicated in SEQ ID No. 172, 174, 176, 178, 180, 182 or 184, especially for the amino acid sequence indicated in SEQ ID No. 172,

c) nucleic acid sequences which hybridize with the complementary strand of the nucleic acid sequences indicated a) or b) above, especially of the nucleic acid sequence indicated in SEQ ID No. 1, under stringent conditions,

d) nucleic acid sequences which are at least 60%, 65%, 70%, 75% or 80%, preferably at least 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89% or 90%, particularly preferably at least 91%, 92%, 93%, 94% or 95% and especially at least 96%, 97%, 98% or 99%, identical to the nucleic acid sequences indicated in a) or b) above, especially to the sequence indicated in SEQ ID No. 171, and

e) nucleic acid sequences which code for an amino acid sequence and which have at least one, for example 2, 3, 4, 5,

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.